The QRISK Challenge: A Hidden Opportunity
The QRISK3 assessment tool is valuable in predicting cardiovascular risk. However, its reliance on patient recall and potential for human error can lead to inaccurate assessments. This presents a significant challenge for pharmaceutical companies seeking to identify and target high-risk patient populations.
The Cost of Inaccurate Risk Assessment
Inaccurate cardiovascular risk assessment can lead to:
- Delayed diagnosis of heart disease
- Ineffective treatment plans
- Increased healthcare costs
- Missed opportunities for preventative interventions
These consequences not only impact patient outcomes but also hinder the development and commercialization of life-saving therapies.
Kribado: Your Solution to the QRISK Challenge
Kribado is a revolutionary patient screening device designed to enhance cardiovascular risk assessment. By providing rapid and accurate risk scores, Kribado empowers healthcare providers to:
- Identify high-risk patients early
- Optimize patient management
- Improve clinical trial recruitment
- Drive data-driven decision-making
How Kribado Works
Kribado’s user-friendly interface and advanced algorithms streamline the patient screening process. With a simple touch-screen and embedded printer, healthcare professionals can:
- Collect patient data efficiently
- Generate instant QRISK-based risk scores
- Stratify patients based on risk levels
- Inform personalized treatment plans
Indigital Technologies: Your Partner in Cardiovascular Health
As pharmaceutical business growth experts, Indigital Technologies has a proven track record of driving success for over 653 brands across 8 countries. Our expertise, combined with innovative solutions like Kribado, empowers you to:
- Optimize patient engagement
- Improve clinical trial outcomes
- Enhance brand reputation
- Achieve sustainable growth
With a strong foundation of 3 patents and a stellar service rating of 4.2 stars, we are committed to delivering exceptional value to our clients.